Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dB Segment Context — Pharmaceutical Segment Revenue ($M) ($M)
Postgres DB segment_values (via lib/db.py)
Latest, FY2025
58,142
Period ended Dec 31, 2025
Change on a year earlier
+1.3%
57,400 in FY2024
History
15 years
Since FY2011
Sources
11
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Segment Context — Pharmaceutical Segment Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58,142 | +1.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 57,400 | +7.1% | Form 10-K (filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 53,583 | +3.0% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 52,005 | +21.6% | Form 10-K (filed 2023-02-24) ↗ |
| FY2021 | Dec 31, 2021 | 42,754 | +16.8% | Form 10-K (filed 2022-02-25) ↗ |
| FY2020 | Dec 31, 2020 | 36,610 | +7.4% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 34,100 | -9.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 37,689 | +6.5% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 35,390 | +0.7% | Form 10-K (filed 2018-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 35,151 | +1.1% | SEC Filing ↗ |
| FY2015 | Dec 31, 2015 | 34,782 | -3.5% | Form 10-K (filed 2016-02-26) ↗ |
| FY2014 | Dec 31, 2014 | 36,042 | -3.7% | Form 10-K (filed 2015-02-27) ↗ |
| FY2013 | Dec 31, 2013 | 37,437 | -7.8% | Form 10-K (filed 2014-02-27) ↗ |
| FY2012 | Dec 31, 2012 | 40,601 | -1.7% | Form 10-K (filed 2014-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 41,289 | – | Form 10-K (filed 2014-02-27) ↗ |
Breakdown
What makes up db segment context — pharmaceutical segment revenue ($m)
- Pharmaceutical Segment — Cost of Sales ($M)6,679 · FY2025
- Pharmaceutical Segment — SG&A Expense ($M)5,874 · FY2025
- Pharmaceutical Segment — Segment Profit / Pretax Income ($M)45,754 · FY2025
- Animal Health Segment — Revenue ($M)6,354 · FY2025
- Animal Health Segment — Cost of Sales ($M)2,649 · FY2025
- Animal Health Segment — SG&A Expense ($M)1,125 · FY2025
- Animal Health Segment — Segment Profit / Pretax Income ($M)2,131 · FY2025
Cite this data
StockData. (2026). Merck DB Segment Context — Pharmaceutical Segment Revenue ($M) ($M), annual FY2011–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/db_seg_pharma_rev
See every metric in the Merck KPI table. Data updated Oct 26, 2026.